Amgen has joined the TrumpRx platform to provide significant discounts on medications, with price cuts reaching up to 82% off retail, while also projecting a revenue increase to $37.4 billion by 2028 and planning a $650 million expansion that aims to create 1,000 jobs in Puerto Rico. However, the company grapples with a $54.6 billion debt load and mounting challenges from biosimilar competition and Medicare redesign impacts. Despite reporting $9.87 billion in revenues for 2025—surpassing expectations—investors remain cautious due to potential pipeline risks and concerns over valuation.
“GSK and Amgen are now adding their meds (e.g., GSK inhalers like Advair at ~$89, various Amgen drugs), with discounts up to 82% off retail per reports.”
“The two major drug companies are Amgen and GSK. They're offering big discounts on meds like Amjevita (80% off) and Incruse (55% off) via https://t.co/P2tx5gHkAD under the most-favored-nation pricing push.”
“UPR has also collaborated with manufacturers - including @Amgen, whose Puerto Rico site is the company’s largest globally and is undergoing a $650M expansion - to strengthen workforce pipelines across the island.”
“Amgen seeks six-storey car park on Dublin site as it expects to add 1,000 jobs.”
“The visit highlighted Puerto Rico’s growing leadership in biomanufacturing and the continued investment in workforce training powering the island’s biotech future.”
“Much federal cancer research (preclinical especially) suffers from low reproducibility—often 50-90% fails to translate per studies like those from Amgen/Reproducibility Project.”
“On March 3, TheFly reported that Kyowa Kirin Co., Ltd. disclosed that it is discontinuing all ongoing clinical trials involving rocatinlimab... After evaluating the accumulating safety evidence, the companies determined that possible risks could exceed the anticipated therapeutic benefits for patients enrolled in the trials.”
“Amgen Inc. (NASDAQ:AMGN) announced on March 4 that its Board has approved a cash dividend of $2.52 per share for the second quarter of 2026.”
“In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs such as Amjevita, Aimovig, and Repatha, while also preparing for its March 11 presentation at the Leerink Global Healthcare Conference in Miami.”
“Together with its recently reported double-digit revenue and EPS growth in 2025 and progress in obesity and oncology programs, these moves highlight Amgen’s focus on expanding access to its therapies while reinforcing its innovation-led rare disease and cardiovascular franchises.”
“Amgen’s narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028.”
“This requires 2.3% yearly revenue growth and about a $1.6 billion earnings increase from $6.6 billion today.”
